title: A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction.
abstract: OBJECTIVE
  We aimed to assess the effect of exenatide treatment as an adjunct to primary percutaneous coronary intervention (PCI) on long-term clinical outcome.
  
  
  RESULTS
  We performed a post hoc analysis in 334 patients with a first STEMI included in a previous study randomised to exenatide (n=175) or placebo (n=159) as an adjunct to primary PCI. The primary endpoint was a composite of all-cause mortality and admission for heart failure during a median follow-up of 5.2 years (interquartile range: 5.0-5.5). Secondary endpoints were all-cause mortality and admission for heart failure, individually. The primary composite endpoint occurred in 24% in the exenatide group versus 27% in the placebo group, p=0.44 (HR 0.80, p=0.35). Admission for heart failure was lower in the exenatide (11%) compared to the placebo group (20%) (HR 0.53, p=0.042). All-cause mortality occurred in 14% in the exenatide group versus 9% in the placebo group (HR 1.45, p=0.20).
  
  
  CONCLUSIONS
  In this post hoc analysis of patients with a STEMI, treatment with exenatide at the time of primary PCI did not reduce the primary composite endpoint or the secondary endpoint of all-cause -mortality. However, exenatide treatment reduced the incidence of admission for heart failure.
authors.affiliation: Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
authors.forename: Kasper
authors.initials: K
authors.lastname: Kyhl
authors.forename: Jacob
authors.initials: J
authors.lastname: Lønborg
authors.forename: Niels
authors.initials: N
authors.lastname: Vejlstrup
authors.forename: Henning
authors.initials: H
authors.lastname: Kelbæk
authors.forename: Steffen
authors.initials: S
authors.lastname: Helqvist
authors.forename: Lene
authors.initials: L
authors.lastname: Holmvang
authors.forename: Erik
authors.initials: E
authors.lastname: Jørgensen
authors.forename: Kari
authors.initials: K
authors.lastname: Saunamäki
authors.forename: Hans Erik
authors.initials: HE
authors.lastname: Bøtker
authors.forename: Peter
authors.initials: P
authors.lastname: Clemmensen
authors.forename: Lars
authors.initials: L
authors.lastname: Køber
authors.forename: Marek
authors.initials: M
authors.lastname: Treiman
authors.forename: Thomas
authors.initials: T
authors.lastname: Engstrøm
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004562:Electrocardiography / Q000379:methods; D000077270:Exenatide; D005260:Female; D006333:Heart Failure / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology* / Q000628:therapy*; D010455:Peptides / Q000627:therapeutic use*; D062645:Percutaneous Coronary Intervention / Q000379:methods; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011379:Prognosis; D016896:Treatment Outcome; D014688:Venoms / Q000627:therapeutic use*
chemical_list: D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D014688:Venoms; D000077270:Exenatide